TCRX
Tscan Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$69.27M
P/E Ratio
—
EPS
$-0.96
Beta
1.06
52W High
$2.57
52W Low
$0.88
50-Day MA
$1.11
200-Day MA
$1.34
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tscan Therapeutics Inc
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company focused on transforming cancer treatment with its pioneering T cell receptor (TCR) discovery platform, which specifically targets cancer antigens to deliver precision immunotherapy. By leveraging groundbreaking scientific advancements, Tscan is dedicated to developing effective TCR-based therapeutics that aim to enhance treatment options across a spectrum of malignancies. With a promising pipeline and strong intellectual property assets, the company is well-positioned to play a significant role in the expanding T cell-based cancer therapy market, addressing pressing unmet medical needs and contributing to improved patient outcomes.
Fundamentals
| Revenue (TTM) | $9.14M |
| Gross Profit (TTM) | $-95.53M |
| EBITDA | $-123.82M |
| Operating Margin | -2967.00% |
| Return on Equity | -80.90% |
| Return on Assets | -29.60% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $2.16 |
| Price-to-Book | 0.71 |
| Price-to-Sales (TTM) | 7.58 |
| EV/Revenue | 3.694 |
| EV/EBITDA | 0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -54.80% |
| Shares Outstanding | $61.07M |
| Float | $55.38M |
| % Insiders | 0.20% |
| % Institutions | 59.39% |
Historical Volatility
HV 10-Day
73.80%
HV 20-Day
71.70%
HV 30-Day
95.19%
HV 60-Day
78.43%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
1
Strong Buy4
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026